Update to the PAC: Atypical Antipsychotics in the Pediatric Population Judith U. Cope, MD, MPH Office of Pediatric Therapeutics OC, FDA - Extrapyramidal - Document - PDFSEARCH.IO

First Page	Meta Content
	Update to the PAC: Atypical Antipsychotics in the Pediatric Population Judith U. Cope, MD, MPH Office of Pediatric Therapeutics OC, FDA Add to Reading List Open Document File Size: 36,74 KB Share Result on Facebook Company NIH Working Group / BPCA Atypical Antipsychotics Working Group / / OperatingSystem OSE / / Organization MPH office of Pediatric Therapeutics OC / FDA office of Pediatric Therapeutics / FDA Pediatric Advisory Committee / FDA Division of Epidemiology/OSE / Psychopharmacologic Drug Advisory Committee / FDA Division of Psychiatry Products / National Institute of Health / / Product Risperidone / Olanzapine / / SocialTag Piperazines Lactams Organofluorides Piperidines Antipsychotic Risperidone Typical antipsychotic Olanzapine Extrapyramidal symptoms Atypical antipsychotics

Update to the PAC: Atypical Antipsychotics in the Pediatric Population Judith U. Cope, MD, MPH Office of Pediatric Therapeutics OC, FDAAdd to Reading List